Formosa Laboratories, Inc. (4746.TW)
TWD 71.9
(-0.96%)
TWD 71.9
(-0.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.42 Billion TWD | 9.52% |
| 2022 | 4.95 Billion TWD | 12.22% |
| 2021 | 4.41 Billion TWD | -11.7% |
| 2020 | 5 Billion TWD | -2.93% |
| 2019 | 5.15 Billion TWD | 23.6% |
| 2018 | 4.16 Billion TWD | 32.68% |
| 2017 | 3.14 Billion TWD | 19.39% |
| 2016 | 2.63 Billion TWD | -12.13% |
| 2015 | 2.99 Billion TWD | 12.76% |
| 2014 | 2.65 Billion TWD | 7.27% |
| 2013 | 2.47 Billion TWD | 4.83% |
| 2012 | 2.36 Billion TWD | 91.41% |
| 2011 | 1.23 Billion TWD | 25.63% |
| 2010 | 981.91 Million TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.31 Billion TWD | 0.22% |
| 2024 Q1 | 5.29 Billion TWD | -2.34% |
| 2023 FY | 5.42 Billion TWD | 9.52% |
| 2023 Q4 | 5.42 Billion TWD | 3.75% |
| 2023 Q3 | 5.22 Billion TWD | -1.57% |
| 2023 Q2 | 5.31 Billion TWD | 10.3% |
| 2023 Q1 | 4.81 Billion TWD | -2.77% |
| 2022 Q1 | 4.24 Billion TWD | -3.9% |
| 2022 Q4 | 4.95 Billion TWD | 5.43% |
| 2022 Q2 | 4.52 Billion TWD | 6.57% |
| 2022 FY | 4.95 Billion TWD | 12.22% |
| 2022 Q3 | 4.69 Billion TWD | 3.94% |
| 2021 Q1 | 5.21 Billion TWD | 4.3% |
| 2021 Q2 | 4.56 Billion TWD | -12.53% |
| 2021 FY | 4.41 Billion TWD | -11.7% |
| 2021 Q3 | 4.38 Billion TWD | -3.94% |
| 2021 Q4 | 4.41 Billion TWD | 0.76% |
| 2020 FY | 5 Billion TWD | -2.93% |
| 2020 Q1 | 5.26 Billion TWD | 2.17% |
| 2020 Q3 | 5.03 Billion TWD | -2.72% |
| 2020 Q4 | 5 Billion TWD | -0.67% |
| 2020 Q2 | 5.17 Billion TWD | -1.68% |
| 2019 FY | 5.15 Billion TWD | 23.6% |
| 2019 Q4 | 5.15 Billion TWD | 9.09% |
| 2019 Q3 | 4.72 Billion TWD | 0.7% |
| 2019 Q2 | 4.68 Billion TWD | 4.27% |
| 2019 Q1 | 4.49 Billion TWD | 7.91% |
| 2018 Q3 | 3.47 Billion TWD | -5.67% |
| 2018 Q2 | 3.68 Billion TWD | 11.85% |
| 2018 Q1 | 3.29 Billion TWD | 4.82% |
| 2018 FY | 4.16 Billion TWD | 32.68% |
| 2018 Q4 | 4.16 Billion TWD | 19.97% |
| 2017 Q1 | 2.57 Billion TWD | -2.0% |
| 2017 Q4 | 3.14 Billion TWD | 7.84% |
| 2017 Q3 | 2.91 Billion TWD | -4.24% |
| 2017 Q2 | 3.04 Billion TWD | 17.97% |
| 2017 FY | 3.14 Billion TWD | 19.39% |
| 2016 Q1 | 3.06 Billion TWD | 2.38% |
| 2016 Q4 | 2.63 Billion TWD | -5.68% |
| 2016 Q2 | 3.25 Billion TWD | 6.31% |
| 2016 FY | 2.63 Billion TWD | -12.13% |
| 2016 Q3 | 2.78 Billion TWD | -14.4% |
| 2015 Q3 | 2.88 Billion TWD | -1.6% |
| 2015 FY | 2.99 Billion TWD | 12.76% |
| 2015 Q4 | 2.99 Billion TWD | 3.72% |
| 2015 Q2 | 2.93 Billion TWD | 5.01% |
| 2015 Q1 | 2.79 Billion TWD | 5.21% |
| 2014 Q2 | 2.38 Billion TWD | 3.52% |
| 2014 Q1 | 2.3 Billion TWD | -6.79% |
| 2014 Q4 | 2.65 Billion TWD | 9.87% |
| 2014 FY | 2.65 Billion TWD | 7.27% |
| 2014 Q3 | 2.41 Billion TWD | 1.18% |
| 2013 Q1 | 2.48 Billion TWD | 5.18% |
| 2013 Q2 | 2.9 Billion TWD | 16.99% |
| 2013 Q3 | 2.58 Billion TWD | -10.91% |
| 2013 Q4 | 2.47 Billion TWD | -4.37% |
| 2013 FY | 2.47 Billion TWD | 4.83% |
| 2012 Q4 | 2.36 Billion TWD | 13.91% |
| 2012 Q1 | 1.39 Billion TWD | 13.36% |
| 2012 Q2 | 1.83 Billion TWD | 31.15% |
| 2012 FY | 2.36 Billion TWD | 91.41% |
| 2012 Q3 | 2.07 Billion TWD | 13.03% |
| 2011 Q3 | 1.02 Billion TWD | 29.89% |
| 2011 Q4 | 1.23 Billion TWD | 20.24% |
| 2011 Q1 | 500.3 Million TWD | -49.05% |
| 2011 Q2 | 789.85 Million TWD | 57.88% |
| 2011 FY | 1.23 Billion TWD | 25.63% |
| 2010 FY | 981.91 Million TWD | 0.0% |
| 2010 Q4 | 981.91 Million TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | -39.776% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | -77.82% |
| Maywufa Company Ltd. | 794.91 Million TWD | -582.587% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | -299.806% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 65.347% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -10610.6% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | -50.828% |
| PhytoHealth Corporation | 79.84 Million TWD | -6695.314% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | -241.088% |
| PharmaEssentia Corporation | 3.32 Billion TWD | -63.376% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 59.161% |